Background: The major trigger of asthma exacerbations is infection with a respira-
| INTRODUCTION
Asthma is an inflammatory disease of the airways characterised by variable airflow obstruction and hyperresponsiveness and is one of the most frequent chronic diseases of young adults. Acute exacerbations are the main cause of morbidity and healthcare utilisation 1 and thus preventing future exacerbations is a key goal in the clinical management of patients with asthma.
Infection with respiratory viruses, particularly rhinoviruses (RV), is a common trigger of asthma exacerbations, but the mechanisms are still unclear. [2] [3] [4] Airway epithelial cells cultured ex vivo from nonasthmatic subjects produce TSLP, IL-25 and IL-33 in response to within 24 hours of contact with the study team. Exacerbations were defined as increased symptoms that required a change in medication as judged by the attending physician, in line with ATS/ERS recommendations. 21 Exacerbations managed by adjusting inhaled therapies were recorded as mild/moderate, whereas exacerbations requiring a course of oral corticosteroids (OCS) or admission to hospital, were considered severe. 21 In addition, patients were instructed to perform a nasal swab at home, when experiencing symptoms of a common cold-patients were not examined further on this occasion. The local scientific ethics committee approved the study (journal nr: H-3-2011-121). All subjects were informed and gave written consent.
| Assessments
Spirometry (EasyOne, NDD, Switzerland) was completed according to ERS recommendations, 22 using NHANES III as the reference. 23 A skin prick test (Soluprick, ALK, Denmark) was completed, and atopy was defined as a positive test (maximum wheal diameter ≥3 mm) to at least one of ten common aeroallergens (grasses, house dust mite, birch, mugwort, dog, cat, horse, cladosporum herbarum and alternaria tenuis). Fractional expiratory nitric oxide (FeNO) was analysed on a NioxMinor (Aerocrine, Solna, Sweden) following the recommendations of the ERS and ATS 24 using the mean of two measurements.
The ATS-defined cut-off of 25 ppb of FeNO was used to define patients with high and low FeNO. Sputum was induced according to the ERS guidelines and processed using a protocol described by Pavord et al. 25 Differential cell counts from cytospins were obtained from 400 non-squamous cells. A cut-off of 1% for sputum eosinophils was applied to define those with high and low sputum eosinophils, as it has been reported to correspond to the 95th percentile of sputum eosinophils in healthy adults. 
| Statistical analyses
The data were analysed with SPSS version 22.0 (IBM SPSS, Armonk, NY, USA). Normally distributed data are reported as meanAEstandard deviation and analysed using student's t test for continuous variables, and chi-squared test for categorical variables. Log-transformed variables are reported as geometric mean (GM) with 95% CI. Non-normally distributed data (eg, cell counts) are reported as median (range), and comparisons were made using Kruskal-Wallis test.
To assess the ability of baseline characteristics to predict risk of exacerbation, a proportional hazards model (Cox regression) was used and adjusted for predefined potential confounders of exacerbation risk, including ICS dose, smoking status, ACQ score and % predicted FEV1 (forced expiratory volume in the first second of expiration) at baseline. As the inflammatory markers examined (FeNO, sputum eosinophils) are highly correlated (both in previous studies and in our data), each marker was tested separately in to avoid multicollinearity. For all analyses a P-value of <.05 was considered significant.
| RESULTS
A total of 112 patients were approached, of which 81 patients agreed to participate ( Figure 1 ). ICS were taken by 73% of patients, with the remaining 27% using short acting beta2-agonists alone. In 18 of the 81 recruited patients (22%), FeNO was elevated at baseline (>25 ppb), and among the 56 patients able to produce a valid sputum sample, 16 patients (20%) had sputum eosinophils >1%.
Eight patients had both high FeNO and high sputum eosinophils.
The clinical characteristics of study subjects are described in Table 1 .
During the follow-up period, 22 participants (27%) developed an exacerbation ( Figure 1 ). No patients had more than one exacerbation during the study period. In 15 of 22 patients with an exacerbation (68%), a respiratory virus was detected at exacerbation, predominantly RV and human coronavirus (HCoV) ( Figure 2 ). A course of oral corticosteroid was prescribed for 36% of patients with an exacerbation, whereas the remaining 64% were managed with a temporary increase in ICS alone. No patients required admission to hospital.
Two patients were treated with antibiotics for suspected bacterial pneumonia, although bacterial cultures were later found to be negative.
Patient characteristics, including age, sex and smoking status,
were not different between those that had an exacerbation and those who did not (Table 1 ). In the exacerbation group, mean FeNO at baseline was higher (24 ppb 95% CI: 17-33, P=.048) compared to the non-exacerbation group (18 ppb 95% CI: [16] [17] [18] [19] [20] . Exacerbation patients also had a higher ACQ score at baseline (1.4AE1.1, P=.011) compared to the non-exacerbation patients (0.8AE0.9). There was a trend for lower prevalence of atopy in the exacerbation group (46% vs 68%, P=.066). Lung function, ICS dose and both sputum and blood differential cell counts were similar between the groups (Table 1 ).
In patients with high sputum eosinophils at baseline, five patients (29%) had a virus-positive exacerbation, compared to the eosinophil low group that had six patients (12%) with a virus-positive exacerba- Figure 3 ).
Proportional hazards models were constructed adjusting for known determinants of exacerbation risk (amount of ICS usage, current smoking, ACQ score and % predicted FEV1) at baseline. All demographic variables (sex, age, BMI) had a P-value >.3 in univariate analyses and were not included in the models. Each inflammatory marker was assessed separately for predicting risk of exacerbation (summarised in Table 2 ). There were too few patients in the virusnegative group for this analysis. Table 3 ). However, the proportion of patients with FeNO >25 was significantly different, and lowest in those with a virus-positive cold and highest in those with a virus-positive exacerbation ( 
| DISCUSSION
In this study, both FeNO >25 ppb and sputum eosinophils >1% were associated with an increased risk of developing a virus-induced
T A B L E 1 Baseline characteristics of patients who developed an exacerbation during follow-up (n=22) and those who did not experience any exacerbations (n=59)
Had an exacerbation (n=22) Had no exacerbation (n=59) P-value -an effect that was lost within 6 months of treatment cessation. 34 Likewise, treatment with the anti-IL-13 antibody Lebrikizumab, reduced the rate of exacerbations by 60% in moderate to severe asthmatics with elevated periostin. 20 Whether the exacerbations that can be prevented with these strategies are predominantly viral or non-viral have yet to be reported, but our data suggests that an effect on virus-induced exacerbations is likely.
None of the participants who only developed upper respiratory tract symptoms had FeNO above 25 ppb, while 40% of those who developed an exacerbation had elevated FeNO. This is in line with our finding that high FeNO increased the risk of virus-induced exacerbation, and suggests that patients with well-controlled type 2 inflammation are more resistant to lower airways involvement when infected with common respiratory viruses. However, for this exploratory outcome the numbers were low, and FeNO levels were not different when analysed as a continuous variable and therefore this needs further exploration in larger studies.
A synergistic effect of allergic sensitisation and viral infection on risk of hospital admission has been described in children. 35 In our study, we did not observe an increased risk of exacerbation (viral or non-viral) in patients sensitised to common aeroallergens, indicating that this association might be more pronounced in paediatric populations.
Studies have found that cross-linking of the high affinity IgEreceptor (FceR1) results in blunted interferon responses to RV, 36, 37 which in turn is associated with ineffective viral clearing 38 and more pronounced asthma symptoms. 39, 40 Furthermore, the anti-IgE antibody omalizumab has been shown to eliminate the return-to-school peaks of exacerbations in a large cohort of asthmatic children, suggestive of a reduction of virus-induced exacerbations. 12 Taken together this indicates that high IgE might play a role in virusinduced asthma exacerbations; however, in our study, high IgE was not associated with an increased risk of virus-induced exacerbations.
With the advent of further antibody treatment options in the coming years, there is a widespread intent to enhance personalised asthma management, by tailoring medication choice and dosage according to the inflammatory phenotype. These treatments are likely to prevent some, but not all, exacerbations. Given that respiratory viruses are a major trigger of exacerbations, understanding how each pathway of airway inflammation influences the risk of virus-induced exacerbation will be a critical step in understanding how to optimise the use of antibody therapies to achieve the best individual patient outcomes.
In conclusion, we have shown that high FeNO and sputum eosinophils at baseline are risk factors for virus-induced exacerbations in a real-life setting. If confirmed in larger studies, this could have implications on the risk assessment of asthma patients.
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